Adeena Jamil

Dr. Adeena Jamil

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2024 in Cardiac Failure Review
Verified
Journal Article
Open access
PDF file
LKLaibah Arshad Khan
Laibah Arshad Khan
AJAdeena Jamil
Adeena Jamil
SGStephen J Greene
Stephen J Greene
Muhammad Shahzeb KhanMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
JBJaved Butler
Javed Butler
Aldosterone is a key regulator of fluid and electrolyte balance in the body. It is often dysregulated in heart failure (HF) and is a key driver of cardiac remodelling and worse clinical outcomes. Potassium regulation is essential for normal cardiac, gastrointestinal and neuromuscular function. Serum potassium fluctuations are largely determined by aldosterone, the final step of the renin–angiotensin–aldosterone system. Dyskalaemia (i.e. hypokalaemia and hyperkalaemia) is prevalent in HF because of the disease itself, its therapies and related comorbidities such as chronic kidney disease. Prognostic implications of abnormal serum potassium follow a U-shaped curve, where both hypokalaemia and hyperkalaemia are associated with adverse outcomes. Hypokalaemia is associated with increased mortality, starting from potassium <4.0 mmol/l but especially at potassium <3.5 mmol/l. Hyperkalaemia, along with increasing arrhythmia risk, limits the use of lifesaving renin–angiotensin–aldosterone system inhibitors, which may have long-term survival implications. The advent of novel potassium binders aims to manage chronic hyperkalaemia and may allow for uptitration and optimal dosing of guideline-recommended therapy. This review discusses the impacts of dyskalaemia in HF, along with management strategies, including the relevance of potassium binder use in optimising HF treatment. Current and potential future aldosterone-modulating therapies, such as non-steroidal mineralocorticoid receptor antagonists and aldosterone synthase inhibitors, are also discussed.

11 January 2025 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
JKJai Kumar
Jai Kumar
MHMisha Hasan
Misha Hasan
SMSana Mohsin
Sana Mohsin
MAMojtaba Hussain Alzaher
Mojtaba Hussain Alzaher
TNTripti Nagar
Tripti Nagar
SKSarwan Kumar
Sarwan Kumar

1 January 2024 in Therapeutic Advances in Cardiovascular Disease
Verified
Journal Article
Open access
KTKhawaja M. Talha
Khawaja M. Talha
TATalal Almas
Talal Almas
AMAbdul Mannan Khan Minhas
Abdul Mannan Khan Minhas
HSHusam Salah
Husam Salah
AJAdeena Jamil
Adeena Jamil
Muhammad Shahzeb KhanMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
Background: The prevalence of heart failure (HF) is increasing among young adults in the United States with pervasive racial and ethnic differences in this population. Objective: To evaluate contemporary associations between race and ethnicity, clinical comorbidities, and outcomes among young to middle-aged adults with HF. Methods: A retrospective analysis was performed using the National Health and Nutrition Examination Survey. All participants with a self-report of HF aged 20–64 years from 2005 to 2018 were included and stratified by race and ethnicity [non-Hispanic (NH) Whites, NH Blacks, and Hispanics]. Data on baseline characteristics including age, sex, marital status, citizenship, education level, body mass index, insurance, waist circumference, cigarette smoking, marijuana use, and relevant clinical comorbidities were included. Weighted logistic regression was performed to estimate adjusted odds ratios (aOR) to determine the association of race and ethnicity with HF. Cox proportional-hazards models were used to assess the association of race and ethnicity with all-cause and cardiac mortality. Results: A total of 1,940,447 young to middle-aged adults had self-reported HF between 2005 and 2018, of whom 61% were NH White, 40% were NH Black, and 22% were Hispanic. When compared with NH White adults, NH Black adults had higher odds of HF adjusted for age, sex, insurance status, marital status, education level, citizenship status, and clinical comorbidities (adjusted aOR 2.63, 95% CI: 1.71–4.05, p < 0.001). There was no significant difference in the odds of HF between Hispanic and NH White adults (aOR 1.18, 95% CI: 0.64–2.18, p = 0.585). NH Black adults had higher mean systolic and diastolic blood pressure, and a comparable or lower burden of cardiovascular and non-cardiovascular clinical comorbidities compared with NH White and Hispanic adults. No statistical significance was noted by race and ethnicity for all-cause and cardiac mortality during a follow-up of 5 years. Conclusion: NH Black young to middle-aged adults were more likely to have HF which may be related to higher blood pressure given the largely similar burden of clinically relevant comorbidities compared with other racial and ethnic groups.

2 October 2024 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
Muhammad Shahzeb KhanMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
AJAdeena Jamil
Adeena Jamil
JJJames L. Januzzi
James L. Januzzi
MSMuteia Shakoor
Muteia Shakoor
MBMonica M. Bennett
Monica M. Bennett
JBJaved Butler
Javed Butler

12 June 2026 in European Heart Journal
Verified
Journal Article
Closed access
JBJaved Butler
Javed Butler
AJAdeena Jamil
Adeena Jamil
DCDavid Z I Cherney
David Z I Cherney
TJTazeen H Jafar
Tazeen H Jafar
JTJeffrey M Testani
Jeffrey M Testani
Muhammad Shahzeb KhanMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
Albuminuria, typically measured by urinary albumin-to-creatinine ratio, is present in nearly half of all patients with heart failure. Even at low levels, albuminuria is a well-established, independent risk marker for incident heart failure and adverse outcomes in those with pre-existing heart failure. Currently, routine urinary albumin-to-creatinine ratio screening is not universally recommended in heart failure guidelines, unlike in guidelines for Type 2 diabetes, chronic kidney disease, and hypertension. Emerging data suggest that this may limit opportunities for early detection, risk stratification, and pharmacologic intervention to improve outcomes. Clinical trials of guideline-directed therapies, including renin-angiotensin inhibitors, sodium-glucose cotransporter 2 inhibitors and finerenone show that reductions in urinary albumin-to-creatinine ratio is associated with risk reductions for cardiovascular, heart failure, and chronic kidney disease outcomes, indicating that albuminuria may function as both a marker of risk and potentially a modifiable factor. This review evaluates the role of albuminuria in predicting heart failure development and progression, its potential as a modifiable risk factor, approaches for measurement, current guideline recommendations for testing, and how heart failure therapies influence albuminuria and associated outcomes.

7 January 2026 in Journal of Arrhythmia
Verified
Journal Article
Open access
ORObaid Ur Rehman
Obaid Ur Rehman
WRWaqas Rasheed
Waqas Rasheed
AJAdeena Jamil
Adeena Jamil
EFEeshal Fatima
Eeshal Fatima
TSTariq Jamal Siddiqi
Tariq Jamal Siddiqi
Jishanth MattumpuramJishanth Mattumpuram
Jishanth Mattumpuram
Background: Research regarding the adverse outcomes of atrial fibrillation (AF) in patients with acute pancreatitis (AP) is limited. We hypothesize that the presence of AF is associated with worse inpatient outcomes, including increased mortality and complications in patients admitted with AP. Methods: In this cohort study, de‐identified patient data from the US Collaborative Network in TriNetX was used to assess the risk of all‐cause mortality and adverse events in patients with AP having AF compared to those without AF within 30 days of the index event from January 1, 2010 to July 6, 2024. Analyses were performed before and after propensity score matching, with risks expressed as odds ratios (OR) with 95% confidence intervals (95% CI), and Kaplan–Meier curves were generated for outcomes. Results: A total of 267 429 patients with AP were identified, of whom 44 621 had a diagnosis of AF. Patients with AP having AF presented with higher comorbidity burdens compared to the non‐AF cohort before propensity score matching. After matching, patients with AF exhibited increased risks of all‐cause mortality (OR, 1.24; 95% CI, 1.18–1.3), acute kidney injury (OR, 1.17; 95% CI, 1.14–1.2), deep venous thrombosis (OR, 1.33; 95% CI, 1.27–1.39), hemorrhage (OR, 1.06; 95% CI, 1.01–1.11), severe sepsis (OR, 1.3; 95% CI, 1.25–1.35), and requiring critical care services (OR, 1.19; 95% CI, 1.16–1.23). Conclusion: Our results suggest that AF significantly increases the risk of mortality in patients with AP, even after accounting for confounding etiological, comorbid, and pharmacological factors.